The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL)

This is a Human Clinical Trial study (also classified as: Phase 3).

November 3, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To examine how age affects patient-reported outcomes in patients with advanced-stage classic Hodgkin lymphoma in the S1826 trial.
Analyzed cross-network Phase III trial data of patients aged >12 years with advanced-stage cHL.
Assessed fatigue and neuropathy using structured questionnaires before and at specified intervals after treatment.
Utilized linear regression adjusting for baseline PRO scores and other factors, including age groups and International Prognostic Score.
Younger and older patients reported worse fatigue during treatment, while older patients had better neuropathy outcomes.
Fatigue scores did not significantly differ by treatment arm but varied by age group.
Global health scores indicated better quality of life for adults treated with nivolumab plus doxorubicin compared to the other treatment.

We only have this paper's title and publication details.

Phase III trial found age influences fatigue and neuropathy in advanced-stage cHL, suggesting tailored interventions may be beneficial.

No takes yet. Share an insight, caveat, or question.

Davison et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share